Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis

The development of psoriasis and alopecia areata (AA) is multifactorial. The interleukin-17 (IL-17) cytokine is believed to be associated with the pathophysiology of both diseases. This case report demonstrates a 64-year-old female patient who experienced a new onset of AA after the initiation of IL...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Esther, Thomson, Olivia, Smith, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292069/
https://www.ncbi.nlm.nih.gov/pubmed/37378242
http://dx.doi.org/10.7759/cureus.38986
Descripción
Sumario:The development of psoriasis and alopecia areata (AA) is multifactorial. The interleukin-17 (IL-17) cytokine is believed to be associated with the pathophysiology of both diseases. This case report demonstrates a 64-year-old female patient who experienced a new onset of AA after the initiation of IL-17A inhibitor, secukinumab, for the treatment of her psoriasis. To our knowledge, there are only three case reports specifically discussing IL-17A inhibitors and AA. This case report highlights a potential rare but significant side effect of IL-17A inhibitors. 

Ejemplares similares